Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report

Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine and surgery 2023-02, Vol.85 (2), p.257-260
Main Authors: Gurung, Shekhar, Karki, Saurab, Khadka, Manoj, Bhatta, Bhuwan, Adhikari, Ayush, Shrestha, Amar N
Format: Article
Language:English
Subjects:
Case Reports
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c357t-94ab7383bc847ef322639fa30523bed95c38a102aecaf65e68b41ac0737899183
container_end_page 260
container_issue 2
container_start_page 257
container_title Annals of medicine and surgery
container_volume 85
creator Gurung, Shekhar
Karki, Saurab
Khadka, Manoj
Bhatta, Bhuwan
Adhikari, Ayush
Shrestha, Amar N
description Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.
doi_str_mv 10.1097/MS9.0000000000000198
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9949813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780485646</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-94ab7383bc847ef322639fa30523bed95c38a102aecaf65e68b41ac0737899183</originalsourceid><addsrcrecordid>eNpdUU1PwzAMjRCITWP_AKEcuXQkTdomHJCmiS9pwAE4R27mskLajKRD2r-niIEGvtiWn58_HiHHnE0408XZ3aOesF3jWu2RYcqkTphifH8nHpBxjK9fGJaJPFeHZCByJTPFxZA8zJbBt7WlzQadb3zr7abrU4frN2xqoHVLgRZpskEIiXcL2oBDWgXf0HtcgTunU2ohIg248qE7IgcVuIjjrR-R56vLp9lNMn-4vp1N54kVWdElWkJZCCVKq2SBlUjTXOgKBMtSUeJCZ1Yo4CwFtFDlGeaqlBwsK0ShtOZKjMjFN-9qXTa4sNh2AZxZhbqBsDEeavO30tZL8-I_jNZS95f3BKdbguDf1xg709TRonPQol9HkxaKSZXlMu-h8htqg48xYPU7hjPzJYfp5TD_5ejbTnZX_G36eb74BP-4hOQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780485646</pqid></control><display><type>article</type><title>Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report</title><source>PubMed Central</source><creator>Gurung, Shekhar ; Karki, Saurab ; Khadka, Manoj ; Bhatta, Bhuwan ; Adhikari, Ayush ; Shrestha, Amar N</creator><creatorcontrib>Gurung, Shekhar ; Karki, Saurab ; Khadka, Manoj ; Bhatta, Bhuwan ; Adhikari, Ayush ; Shrestha, Amar N</creatorcontrib><description>Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.</description><identifier>ISSN: 2049-0801</identifier><identifier>EISSN: 2049-0801</identifier><identifier>DOI: 10.1097/MS9.0000000000000198</identifier><identifier>PMID: 36845813</identifier><language>eng</language><publisher>England: Lippincott Williams &amp; Wilkins</publisher><subject>Case Reports</subject><ispartof>Annals of medicine and surgery, 2023-02, Vol.85 (2), p.257-260</ispartof><rights>2023 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-94ab7383bc847ef322639fa30523bed95c38a102aecaf65e68b41ac0737899183</cites><orcidid>0000-0002-0449-9254 ; 0000-0001-5314-3900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949813/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949813/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36845813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gurung, Shekhar</creatorcontrib><creatorcontrib>Karki, Saurab</creatorcontrib><creatorcontrib>Khadka, Manoj</creatorcontrib><creatorcontrib>Bhatta, Bhuwan</creatorcontrib><creatorcontrib>Adhikari, Ayush</creatorcontrib><creatorcontrib>Shrestha, Amar N</creatorcontrib><title>Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report</title><title>Annals of medicine and surgery</title><addtitle>Ann Med Surg (Lond)</addtitle><description>Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.</description><subject>Case Reports</subject><issn>2049-0801</issn><issn>2049-0801</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdUU1PwzAMjRCITWP_AKEcuXQkTdomHJCmiS9pwAE4R27mskLajKRD2r-niIEGvtiWn58_HiHHnE0408XZ3aOesF3jWu2RYcqkTphifH8nHpBxjK9fGJaJPFeHZCByJTPFxZA8zJbBt7WlzQadb3zr7abrU4frN2xqoHVLgRZpskEIiXcL2oBDWgXf0HtcgTunU2ohIg248qE7IgcVuIjjrR-R56vLp9lNMn-4vp1N54kVWdElWkJZCCVKq2SBlUjTXOgKBMtSUeJCZ1Yo4CwFtFDlGeaqlBwsK0ShtOZKjMjFN-9qXTa4sNh2AZxZhbqBsDEeavO30tZL8-I_jNZS95f3BKdbguDf1xg709TRonPQol9HkxaKSZXlMu-h8htqg48xYPU7hjPzJYfp5TD_5ejbTnZX_G36eb74BP-4hOQ</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Gurung, Shekhar</creator><creator>Karki, Saurab</creator><creator>Khadka, Manoj</creator><creator>Bhatta, Bhuwan</creator><creator>Adhikari, Ayush</creator><creator>Shrestha, Amar N</creator><general>Lippincott Williams &amp; Wilkins</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0449-9254</orcidid><orcidid>https://orcid.org/0000-0001-5314-3900</orcidid></search><sort><creationdate>20230201</creationdate><title>Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report</title><author>Gurung, Shekhar ; Karki, Saurab ; Khadka, Manoj ; Bhatta, Bhuwan ; Adhikari, Ayush ; Shrestha, Amar N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-94ab7383bc847ef322639fa30523bed95c38a102aecaf65e68b41ac0737899183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Case Reports</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gurung, Shekhar</creatorcontrib><creatorcontrib>Karki, Saurab</creatorcontrib><creatorcontrib>Khadka, Manoj</creatorcontrib><creatorcontrib>Bhatta, Bhuwan</creatorcontrib><creatorcontrib>Adhikari, Ayush</creatorcontrib><creatorcontrib>Shrestha, Amar N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gurung, Shekhar</au><au>Karki, Saurab</au><au>Khadka, Manoj</au><au>Bhatta, Bhuwan</au><au>Adhikari, Ayush</au><au>Shrestha, Amar N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report</atitle><jtitle>Annals of medicine and surgery</jtitle><addtitle>Ann Med Surg (Lond)</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>85</volume><issue>2</issue><spage>257</spage><epage>260</epage><pages>257-260</pages><issn>2049-0801</issn><eissn>2049-0801</eissn><abstract>Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.</abstract><cop>England</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>36845813</pmid><doi>10.1097/MS9.0000000000000198</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0449-9254</orcidid><orcidid>https://orcid.org/0000-0001-5314-3900</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-0801
ispartof Annals of medicine and surgery, 2023-02, Vol.85 (2), p.257-260
issn 2049-0801
2049-0801
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9949813
source PubMed Central
subjects Case Reports
title Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A30%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20myelomonocytic%20leukemia%20in%20a%2072-year-old%20male%20from%20Nepal:%20A%20case%20report&rft.jtitle=Annals%20of%20medicine%20and%20surgery&rft.au=Gurung,%20Shekhar&rft.date=2023-02-01&rft.volume=85&rft.issue=2&rft.spage=257&rft.epage=260&rft.pages=257-260&rft.issn=2049-0801&rft.eissn=2049-0801&rft_id=info:doi/10.1097/MS9.0000000000000198&rft_dat=%3Cproquest_pubme%3E2780485646%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357t-94ab7383bc847ef322639fa30523bed95c38a102aecaf65e68b41ac0737899183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2780485646&rft_id=info:pmid/36845813&rfr_iscdi=true